PODD250117C390000
- 0.00
- 0.000.00%
Insulet Newsroom
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Citi Maintains Insulet(PODD.US) With Buy Rating
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $315
Analysts Conflicted on These Healthcare Names: Elevance Health (ELV), Agilent (A) and Insulet (PODD)
Insulet To Present At J.P. Morgan 43rd Annual Healthcare Conference; Webcast At 6:45 PM ET
Insulet Launches Omnipod 5 In Five More Countries In Italy, Denmark, Finland, Norway And Sweden
Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe
We Think Insulet (NASDAQ:PODD) Can Stay On Top Of Its Debt
Press Release: Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Bernstein Adjusts Price Target on Insulet to $315 From $305, Keeps Outperform Rating
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $315
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305
Diabetes Device Maker Beta Bionics Files for $100M IPO
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
BofA Securities Maintains Insulet(PODD.US) With Buy Rating, Announces Target Price $305
High Quality Cyclical Stocks According to Morgan Stanley
Express News | Insulet Corp : UBS Raises Target Price to $280 From $253
Wearable Patch Market Report 2025, With Profiles of Key Players Abbott, Medtronic, Dexcom, GlucoWatch, IRhythm Technologies, Insulet, Tactile Medical, VitalConnect, Qardio Myant & BioTelemetry
J.P. Morgan recommends three major gold stocks in Medical Technology for 2025: Boston Scientific, Intuitive Surgical, and Insulet.
JPMorgan selected Boston Scientific and Intuitive Surgical as its preferred Large Cap stocks in the Medical Technology sector in its New Year report, and reaffirmed its favor for the insulin pump manufacturer Insulet in the mid-cap Medical Technology sector.
Here Are J. P. Morgan's Top MedTech Picks for 2025